Follow news, literature and expert opinions on GLP-1 as emerging target in the management of T2DM & Cardiovascular Disease
Patients with T2DM and atherosclerotic poly-vascular disease have a higher CV risk than patients with single vascular disease, and in both groups liraglutide consistently reduced major CV outcomes.
Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.
Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.
Three cardiology and diabetes experts discuss the multifactorial aspect of type 2 diabetes, and the consequential challenges in cardiovascular prevention and management of these patients.
This document covers five topics that help cardiologists understand what is important when treating patients with diabetes, and which risks these patients face. Download your free copy.
5 Things a cardiologist needs to know about diabetes Multiple causal pathways contribute to development of T2DM, thus various processes may be targeted to improve glucose regulation. Prof. Bailey briefly summarises the available therapeutic options.
A meta-analysis of available CV outcome trials with GLP-1 receptor agonists shows that they reduce major adverse cardiovascular events in type 2 diabetes patients without significant safety concerns.
5 Things a cardiologist needs to know about diabetes Prof Leiter gives an update of the trials on new antihyperglycemic drugs (DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors) that have been completed or are ongoing since the FDA mandated demonstration of CV safety.
Data of the PIONEER 1 study show that treatment with the highest tested dose of oral semaglutide in adults with T2DM safely lowered HbA1c by 1.5% at 26 weeks, and yielded a mean 4.1 kg weight loss.
Prof. Neil Poulter gives an overview of a subgroup analysis of the LEADER trial in which patients with CKD treated with liraglutide showed a reduction of CV events as compared with those on placebo treatment.
Dr. Stephen Wiviott explains how a change in regulatory guidance has dramatically altered the trial landscape and drug development for type 2 diabetes mellitus and has provided substantial information related to CV disease.
Based on the results of the SUSTAIN trial, semaglutide is approved by the FDA for the treatment of T2DM patients.